CK-MB Activity vs. CK-MB Mass: Key Differences
CK-MB mass assays offer superior analytical and diagnostic performance compared to CK-MB activity assays and are strongly preferred for clinical use. 1
What They Measure
- CK-MB activity measures the enzymatic activity (catalytic function) of the CK-MB isoenzyme, reported in units per liter (U/L) 2
- CK-MB mass measures the actual protein concentration of CK-MB using immunoassay techniques, reported in micrograms per liter (μg/L or ng/mL) 2, 3
Why Mass Assays Are Superior
Analytical Performance
- CK-MB mass demonstrates better precision and less scatter in serial measurements, particularly at lower CK-MB levels (< 500 IU/L), with superior correlation coefficients when fitting time-value curves (0.97 vs 0.93) 4
- Mass assays eliminate interference from atypical CK isoforms and CK-BB that can falsely elevate CK-MB activity results measured by immunoinhibition methods 5, 6
- Mass assays have better analytical specificity because they use monoclonal antibody sandwich techniques rather than enzymatic inhibition 1, 2
Clinical Performance
- CK-MB mass rises earlier than CK-MB activity after myocardial injury, with a median difference of approximately 1 hour, allowing earlier diagnosis of acute MI 3
- Mass assays show significantly higher diagnostic sensitivity in the critical 0-6 hour window after symptom onset, when decisions about thrombolytic therapy are made 3
- CK-MB mass reaches diagnostic cutoff levels before CK-MB activity, making it clinically superior for detecting reinfarction 5
Kinetic Differences
- CK-MB mass disappears from serum faster than CK-MB activity (0.54 hr⁻¹ vs 0.28 hr⁻¹), suggesting that some CK-MB activity becomes inactivated early after release from necrotic myocardium while the protein mass remains detectable 4
- Both markers typically rise 3-4 hours after myocardial injury onset and remain elevated for 24-36 hours 1
Important Clinical Caveats
Skeletal Muscle Interference
- Both CK-MB mass and activity can be falsely elevated in muscular diseases (e.g., muscular dystrophy), as CK-MB constitutes 1-3% of skeletal muscle CK 1, 7
- In patients with muscular disease, CK-MB mass remains significantly elevated even after treatment, while cardiac troponin I remains normal, demonstrating the limitation of CK-MB mass for assessing myocardial injury in this population 7
When Discordance Occurs
- If CK-MB activity is abnormally elevated but clinical findings don't support acute MI, measure CK-MB mass to eliminate interference from atypical CK isoforms 6
- Concordance between mass and activity measurements is excellent (96% agreement, r=0.94) when using monoclonal antibody-based assays 2
- However, the two methods are not analytically interchangeable and cannot replace one another despite good correlation 5
Current Clinical Context
- Cardiac troponin is now the preferred biomarker for myocardial injury detection due to superior cardiac specificity 1
- When troponin is unavailable, CK-MB measured by mass assay is the next best alternative 1
- CK-MB activity assays should not be used if mass assays are available 1
- Total CK activity is not recommended for MI diagnosis due to poor cardiac specificity 1, 8